Pacira Biosciences' Exparel Generic Application Status for 2025
Pacira Biosciences' Exparel, a liposomal bupivacaine injectable used for postsurgical pain management, is facing potential generic competition. As of early 2024, several companies have filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for generic versions of Exparel [1].
What are the key dates for Exparel's patent and exclusivity?
Exparel's primary patents are set to expire, opening the door for generic entrants [2]. While specific patent expiration dates vary, the landscape suggests that 2025 is a significant year for potential generic launches [2]. DrugPatentWatch.com tracks these patent expirations, providing detailed timelines for pharmaceutical products [3].
Which companies are seeking to market generic Exparel?
Several pharmaceutical manufacturers have filed ANDAs for generic Exparel. These include companies like Teva Pharmaceuticals and Hikma Pharmaceuticals, among others who are looking to enter the market once patents and exclusivity periods expire [1][4].
What is the FDA's role in approving generic Exparel?
The FDA reviews ANDAs to ensure that generic drugs are bioequivalent to their brand-name counterparts. Approval of an ANDA signifies that the generic version meets the same safety and efficacy standards as Exparel [1].
How do generic Exparel applications impact Pacira Biosciences?
The potential approval of generic Exparel applications represents a significant commercial challenge for Pacira Biosciences. The introduction of lower-cost generic alternatives typically leads to a substantial decrease in the market share and revenue for the brand-name drug [5]. Pacira has actively defended its intellectual property in the past [6].
What are the potential clinical implications of generic Exparel?
For patients, the availability of generic Exparel could lead to lower healthcare costs. Clinically, generic versions are expected to offer the same pain relief and safety profile as the branded product, as they must demonstrate bioequivalence [1][5].
When can generic Exparel be expected to launch?
While ANDA filings indicate intent, actual generic launch dates depend on patent litigation outcomes, the FDA's review process, and any remaining market exclusivity. The year 2025 is frequently cited as a key period for potential generic Exparel availability, though specific launch dates can be fluid [2][3].